James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $577.86, for a total value of $5,778,600.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,907,685.36. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Price Performance

NASDAQ UTHR opened at $574.29 on Thursday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $607.89. The stock’s 50-day moving average is $532.71 and its two-hundred day moving average is $492.68. The firm has a market cap of $25.17 billion, a P/E ratio of 20.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company earned $6.19 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP grew its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC grew its position in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares in the last quarter. Janus Henderson Group PLC grew its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares in the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics during the third quarter worth about $317,617,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada lifted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company lifted their price objective on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $601.50.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Company to present encouraging clinical and program data (ARTISAN/PHINDER interim analyses) at ISHLT — results highlight earlier detection/management of pulmonary hypertension, right‑ventricular benefits with high‑dose treprostinil, and progress on lung donor expansion/xenotransplantation, which support longer‑term pipeline value and revenue upside. Read More.
• Positive Sentiment: Analysts remain constructive with multiple price‑target raises and a consensus “Moderate Buy” (~$601.50 average), which provides valuation support that can limit downside if upcoming clinical/earnings news is positive.
• Positive Sentiment: Longer‑term bull thesis highlighted around manufactured organs/xenotransplantation — bullish pieces argue these programs (if successful and approved) could materially re‑rate the company over the next several years. Read More.
• Neutral Sentiment: United Therapeutics will report Q1 results before market open on May 6; Zacks notes the company has setup attributes that could support an earnings beat — this calendar catalyst can drive short‑term volatility in either direction. Read More. Read More.
• Neutral Sentiment: Some institutional reweighting — Asset Management One modestly trimmed its stake (≈5.1%), a small adjustment rather than a large outflow that’s unlikely to move the stock materially on its own. Read More.
• Neutral Sentiment: Unusually large options activity has been reported, indicating elevated short‑term trading and hedging interest — this can amplify intraday moves but is directionally ambiguous. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.5M) in mid‑April, reducing her stake by ~19% — a high‑profile insider sale that often raises investor concerns about near‑term sentiment. Read More.
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) around the same dates — multiple senior executive sales in quick succession increase perceived selling pressure. Read More.
• Negative Sentiment: Additional director insider sales have been reported, adding to the pattern of recent insider liquidations that can weigh on near‑term investor sentiment. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.